The Journal of the National Cancer Institute (JNCI) reported new findings from the (GEMCAD)-1402 trial, which investigated the addition of aflibercept in the treatment of locally advanced rectal adenocarcinoma.
Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402
Posted in biotech/medical